This grant is to provide support for the Statistics and Data Management Center (SDMC) of the ECOG- ACRIN Cancer Research Group. The SDMC provides methodologic expertise, leadership, and support for the effective design and conduct of studies and collaborates in the management of NCTN. The Center has a streamlined leadership and organizational structure for its four offices located at the Department of Biostatistics and Computational Biology at the Dana-Farber Cancer Institute (DFCI), the Department of Biostatistics, Center for Statistical Sciences at Brown University, the Frontier Science and Technology Research Foundation (FSTRF), and the American College of Radiology (ACR), under the direction of the Group Statisticians. The primary responsibility for data collection and management belongs to the Data Management Center, with offices in Boston (FSTRF) and Philadelphia (ACR). The primary responsibility for study design, monitoring, and analysis, and for overseeing and coordinating SDMC operations belongs to the Biostatistics Center, with offices in Boston (DFCI) and Providence (Brown University);The prime contact site for grant administration is DFCI.

Public Health Relevance

The primary goals of the SDMC are to provide methodologic expertise, leadership, and support in the design, development, implementation, and analysis of NCTN studies led by ECOG-ACRIN, to provide efficient and timely data collection and management of those studies, and to participate actively in all aspects of the collective management of the NCTN.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
1U10CA180794-01
Application #
8605248
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Mooney, Margaret M
Project Start
2014-04-29
Project End
2019-02-28
Budget Start
2014-04-29
Budget End
2015-02-28
Support Year
1
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02215
Zhao, Fengmin; Cella, David; Manola, Judith et al. (2017) Fatigue among patients with renal cell carcinoma receiving adjuvant sunitinib or sorafenib: patient-reported outcomes of ECOG-ACRIN E2805 trial. Support Care Cancer :
Haas, Naomi B; Manola, Judith; Dutcher, Janice P et al. (2017) Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial. JAMA Oncol 3:1249-1252
Butterfield, Lisa H; Zhao, Fengmin; Lee, Sandra et al. (2017) Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697). Clin Cancer Res 23:5034-5043
Wakelee, Heather A; Dahlberg, Suzanne E; Keller, Steven M et al. (2017) Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 18:1610-1623
Sparano, Joseph A; Gray, Robert; Oktay, Maja H et al. (2017) A metastasis biomarker (MetaSite Breastâ„¢ Score) is associated with distant recurrence in hormone receptor-positive, HER2-negative early-stage breast cancer. NPJ Breast Cancer 3:42
Erbe, Amy K; Wang, Wei; Goldberg, Jacob et al. (2017) FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma. Clin Cancer Res 23:2159-2168
Bernard, Brandon; Muralidhar, Vinayak; Chen, Yu-Hui et al. (2017) Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer. Cancer 123:1536-1544
Atri, Mostafa; Zhang, Zheng; Dehdashti, Farrokh et al. (2017) Utility of PET/CT to Evaluate Retroperitoneal Lymph Node Metastasis in High-Risk Endometrial Cancer: Results of ACRIN 6671/GOG 0233 Trial. Radiology 283:450-459
Bolan, Patrick J; Kim, Eunhee; Herman, Benjamin A et al. (2017) MR spectroscopy of breast cancer for assessing early treatment response: Results from the ACRIN 6657 MRS trial. J Magn Reson Imaging 46:290-302
Zhou, Jun; Mahoney, Kathleen M; Giobbie-Hurder, Anita et al. (2017) Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade. Cancer Immunol Res 5:480-492

Showing the most recent 10 out of 157 publications